AdaptHealth (NASDAQ:AHCO) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

AdaptHealth (NASDAQ:AHCO - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.12, Zacks reports. AdaptHealth had a positive return on equity of 9.62% and a negative net margin of 6.57%. The company had revenue of $856.60 million for the quarter, compared to the consensus estimate of $829.19 million. During the same period last year, the business posted ($1.91) earnings per share. The firm's revenue was down .2% compared to the same quarter last year. AdaptHealth updated its FY 2025 guidance to EPS.

AdaptHealth Stock Performance

AHCO traded up $0.29 during trading on Friday, reaching $11.38. 1,758,793 shares of the company's stock were exchanged, compared to its average volume of 1,099,112. The company has a market capitalization of $1.53 billion, a P/E ratio of -6.90, a PEG ratio of 1.08 and a beta of 1.12. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 1.34. The business has a 50 day moving average price of $9.89 and a 200 day moving average price of $10.22. AdaptHealth has a fifty-two week low of $8.35 and a fifty-two week high of $11.90.

Analyst Ratings Changes

A number of brokerages have recently commented on AHCO. Canaccord Genuity Group upped their price target on AdaptHealth from $13.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday. Robert W. Baird boosted their target price on shares of AdaptHealth from $14.00 to $16.00 and gave the stock an "outperform" rating in a research report on Thursday. Truist Financial increased their price target on shares of AdaptHealth from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday. Royal Bank of Canada boosted their price objective on shares of AdaptHealth from $11.00 to $14.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, UBS Group cut their price objective on shares of AdaptHealth from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $13.80.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.